Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC

• Published in: Clinical and translational radiation oncology Vol. 43; p. 100682
• Main Authors: MacManus, Michael, Kirby, Laura, Blyth, Benjamin, Banks, Owen, Martin, Olga A., Yeung, Miriam M., Plumridge, Nikki, Shaw, Mark, Hegi-Johnson, Fiona, Siva, Shankar, Ball, David, Wong, Stephen Q.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.11.2023; Elsevier
• Subjects: Case Report; Chemoradiotherapy; Circulating tumor DNA; Radiotherapy; FDG-PET; ddPCR; RT; NSCLC; SABR; Radiotherapy; Chemoradiotherapy; ctDNA; Circulating tumor DNA
• ISSN: 2405-6308; 2405-6308
• DOI: 10.1016/j.ctro.2023.100682

•Early circulating tumor DNA dynamics following radiotherapy has not been well studied.•ctDNA levels were associated with treatment responses.•A rapid increase in ctDNA levels was observed in a subset of patients.•We propose early ctDNA dynamics should be studied further as a potential biomarker. The kinetics of circulating tumor DNA (ctDNA) release following commencement of radiotherapy or chemoradiotherapy may reflect early tumour cell killing. We hypothesised that an increase in ctDNA may be observed after the first fraction of radiotherapy and that this could have clinical significance. ctDNA analysis was performed as part of a prospective, observational clinical biomarker study of non-small cell lung cancer (NSCLC) patients, treated with curative-intent radiotherapy or chemoradiotherapy. Blood was collected at predefined intervals before, during (including 24 h after fraction 1 of radiotherapy) and after radiotherapy/chemoradiotherapy. Mutation-specific droplet digital PCR assays used to track ctDNA levels during and after treatment. Sequential ctDNA results are available for 14 patients with known tumor-based mutations, including in EGFR, KRAS and TP53, with a median follow-up of 723 days (range 152 to 1110). Treatments delivered were fractionated radiotherapy/chemoradiotherapy, in 2–2.75 Gy fractions (n = 12), or stereotactic ablative body radiotherapy (SABR, n = 2). An increase in ctDNA was observed after fraction 1 in 3/12 patients treated with fractionated radiotherapy with a complete set of results, including in 2 cases where ctDNA was initially undetectable. Neither SABR patient had detectable ctDNA immediately before or after radiotherapy, but one of these later relapsed systemically with a high detected ctDNA concentration. A rapid increase in ctDNA levels was observed after one fraction of fractionated radiotherapy in three cases. Further molecular characterization will be required to understand if a “spike” in ctDNA levels could represent rapid initial tumor cell destruction and could have clinical value as a surrogate for early treatment response and/or as a means of enriching ctDNA for mutational profiling.